Small molecule · Inhibitor of histone deacetylase 1 (HDAC1) and histone deacetylase 4 (HDAC4) · developed by OnKure
Bocodepsin is an orally bioavailable inhibitor of histone deacetylase subtypes 1 and 4 (HDAC1/4). By blocking these enzymes it increases chromatin histone acetylation, altering gene expression and inducing apoptosis in tumor cells that overexpress HDAC1/4. It is being studied in advanced solid tumors, including NRAS-mutated melanoma, in combination with binimetinib.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05340621 | Phase 1/2 | RAS Mutation | Completed | OKUR |
| NCT03931681 | Phase 1 | Advanced Solid Tumors | Completed | OKUR |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Advanced Solid TumorsMelanomaNRAS Gene MutationRAS Mutation
Updated Oct 25, 2026. Something wrong or missing? Report it on the OKUR page.
See OKUR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
OKUR catalysts and pipeline →